Document is current
Any future updates will be listed below
-
Authors
Galarza Fortuna, Gliceida M. https://orcid.org/0000-0002-1084-953X
Grass, Daniel
Maughan, Benjamin L
Jain, Rohit K
Dechet, Christopher
Beck, Julia
Schuetz, Ekke
Sanchez, Alejandro
O’Neil, Brock
Poch, Michael
Li, Roger
Lloyd, Shane
Tward, Jonathan
Phunrab, Tenzin
Hawks, Josiah Lyn https://orcid.org/0000-0001-9908-4598
Swami, Umang https://orcid.org/0000-0003-3518-0411
Boucher, Kenneth M
Agarwal, Neeraj https://orcid.org/0000-0003-1076-0428
Gupta, Sumati https://orcid.org/0000-0001-6271-0831
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03171025 at ClinicalTrials.govnct03171025 at ClinicalTrials.govDocuments that mention this clinical trial
NEXT: A phase 2 study of nivolumab adjuvant to chemoradiation in patients (pts) with localized urothelial carcinoma.
https://doi.org/10.1200/jco.2024.42.4_suppl.612
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)
https://doi.org/10.1136/jitc-2024-010572
nct03775265 at ClinicalTrials.govDocuments that mention this clinical trial
NEXT: A phase 2 study of nivolumab adjuvant to chemoradiation in patients (pts) with localized urothelial carcinoma.
https://doi.org/10.1200/jco.2024.42.4_suppl.612
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)
https://doi.org/10.1136/jitc-2024-010572
Documents that mention this clinical trial
Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)
https://doi.org/10.1136/jitc-2024-010572
Healthcare provider evaluation of machine learning-directed care: reactions to deployment on a randomised controlled study
https://doi.org/10.1136/bmjhci-2022-100674
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
https://doi.org/10.1136/jitc-2021-002552
-
Funding
Funding for this research was provided by:
Biomedical Laboratory Research and Development, VA Office of Research and Development (1I01BX005765)
Bristol Myers Squibb Pharmaceutical (N/A)
- License Information
